Please login to the form below
Kite
This page shows the latest Kite news and features for those working in and with pharma, biotech and healthcare.
Kite’s new CAR T-cell therapy manufacturing facility given the go-ahead by the FDA
The site, situated in the US, is set to produce Kite’s FDA-approved CAR T-cell therapy used to treat blood cancers. ... strengthen our ability to meet the needs of people living with difficult-to-treat blood cancers,” said Christi Shaw, CEO of Kite.
Latest news
-
BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
Following the acquisition, BioNTech will also extend its cell therapy pipeline using the TCR platform from Kite. ... Kite has already seen success with its own CAR T treatments, which includes Tecartus (brexucabtagene autoleucel) and Yescarta
-
Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study
Gilead company Kite has unveiled positive results for its CAR-T therapy Yescarta in the second-line setting for relapsed or refractory large B-cell lymphoma (LBCL). ... As the leader in cell therapy, Kite is honoured to deliver this landmark study and
-
Kite partners with Shoreline Biosciences to develop allogeneic cell therapies
Kite – a Gilead company – has entered into a strategic partnership with Shoreline Biosciences to develop novel allogeneic cell therapies across a range of cancer targets. ... Earlier this year, Kite signed a research collaboration agreement with
-
Yescarta gains first FDA approval for indolent follicular lymphoma
First CAR-T cell therapy to be approved in this indication. Gilead subsidiary Kite's Yescarta has been granted accelerated approval from the US Food and Drug Administration (FDA) for indolent ... Kite also recently revealed some positive data for
-
FDA approves BMS’ blood cancer CAR T therapy after delay
Breyanzi joins other approved CAR T therapies on the market from Gilead/Kite and Novartis. ... Gilead/Kite’s Yescarta (axicabtagene ciloleucel) was the first FDA-approved CAR T therapy for the treatment of adult patients with relapsed or refractory LBCL
More from news
Approximately 24 fully matching, plus 72 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers Squibb’s acquisition of Juno Therapeutics, as well as the merger and acquisition agreements between Novartis/Spark and
-
Drug launches to watch in 2019
1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene
-
Deal Watch October 2018
Gilead’s subsidiary, Kite, has agreed a deal for a research collaboration with HiFiBiO Therapeutics, the Hong Kong-based company which is working on the discovery of therapeutic antibodies through single
-
The European Medicines Agency: PRIME’d for access?
Early signs are looking good: Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June
-
Bluebird Bio: on the cusp of a gene therapy revolution
drugs, Novartis’ Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’ gene therapy Luxturna all reaching the market last year. ... Spark has signed a marketing deal with Novartis in Europe, which means the big pharma company will set the
More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.
Latest appointments
-
New hires at Abbott, Kite and Arrakis Therapeutics
Kite . Kite, a Gilead company, has appointed two new additions to its leadership team. ... Also joining Kite is Ken Takeshita, who has been appointed as global head of clinical development.
-
PureTech Health appoints new chief financial officer
Muijrers has worked with pharmaceutical clients such as Kite Pharma, Ablynx and Juno Therapeutics, and said: “I am thrilled to join PureTech Health, one of the most exiciting and unique biopharma
-
Gilead Sciences promotes Dr Alessandro Riva to EVP, oncology therapeutics
Dr Riva joined the biopharmaceutical group in January 2017, and his previous role saw him take responsibility in expanding Gilead’s oncology programme with the recent acquisition of Kite Pharma. ... John McHutchinson, executive vice president, clinical
-
Sanofi biologics supply VP joins Kite Pharma
Dr Jian Irish becomes senior vice president of supply chain. California-based Kite Pharma has appointed Dr Jian Irish as senior vice president of supply chain. ... Tim Moore, executive vice president of technical operations at Kite Pharma, said: “Jian
-
Former Roche CEO and chairman joins Arix Bioscience
He is currently chairman of Diageo, a consumer goods company, and a non-executive director of Chugai P harmaceuticals, Citigroup and Kite Pharma.
More from appointments
Approximately 4 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Understanding the evolving CAR-T market
Big pharma also wanted a slice of the action. Aggressive deal-making quickly became central to the rise of CAR-T, with Gilead acquiring Kite Pharma for a mammoth $11.9bn
-
Training the next generation of biotech leaders
In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.
-
How do you define a biotech company?
This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- A new era for UK-Japanese scientific research relations
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- Sanofi Global Health unveils new nonprofit Impact brand
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- A creative awakening – how pharma is bringing innovation to the patient journey
- Behaviour change – a maze of decisions influenced by personal habits, experiences and intentions
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Delivering content to fuel omnichannel engagement
PMHub
Mednet Group
PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
